taniborbactam
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02955459)
Timeline
Indications
Mechanism of action
- ADC-14 proteinINHIBITOR
adc-14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NCCNC1CCC(CC(=O)N[C@H]2Cc3cccc(C(=O)O)c3OB2O)CC1- Mol. weight
- 389.26 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594290 ↗
Also known as
- vnrx-5133
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06168734 | Phase 3 | Dec 31, 2023 | Department of Health and Human Services, VenatoRx Pharmaceuticals, Inc. |
| NCT04951505 | Phase 1 | Jun 29, 2021 | VenatoRx Pharmaceuticals, Inc. |
| NCT03840148 | Phase 3 | Jul 31, 2019 | VenatoRx Pharmaceuticals, Inc. |
| NCT03870490 | Phase 1 | Mar 14, 2019 | National Institutes of Health (NIH), VenatoRx Pharmaceuticals, Inc. |
| NCT03690362 | Phase 1 | Apr 6, 2018 | National Institutes of Health (NIH), VenatoRx Pharmaceuticals, Inc. |
| NCT03332732 | Phase 1 | Oct 24, 2017 | National Institute of Allergy and Infectious Diseases (NIAID), VenatoRx Pharmaceuticals, Inc. |
| NCT02955459 | Phase 1 | Nov 1, 2016 | National Institute of Allergy and Infectious Diseases (NIAID), VenatoRx Pharmaceuticals, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| VenatoRx Pharmaceuticals, Inc. | For profit | 7 | 7 | 2 | 2016 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 0 | 1 | 2016 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2018 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1